KUKJEON PHARMACEUTICAL Statistics

Total Valuation

KUKJEON PHARMACEUTICAL has a market cap or net worth of KRW 212.22 billion. The enterprise value is 234.73 billion.

Market Cap	212.22B
Enterprise Value	234.73B

Important Dates

The next estimated earnings date is Wednesday, November 13, 2024.

Earnings Date	Nov 13, 2024
Ex-Dividend Date	n/a

Share Statistics

KUKJEON PHARMACEUTICAL has 49.07 million shares outstanding. The number of shares has increased by 5.99% in one year.

Shares Outstanding	49.07M
Shares Change (YoY)	+5.99%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	61.99%
Owned by Institutions (%)	0.16%
Float	18.65M

Valuation Ratios

The trailing PE ratio is 66.34.

PE Ratio	66.34
Forward PE	n/a
PS Ratio	1.59
PB Ratio	2.14
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 30.08, with an EV/FCF ratio of -28.21.

EV / Earnings	43.84
EV / Sales	1.76
EV / EBITDA	30.08
EV / EBIT	73.39
EV / FCF	-28.21

Financial Position

The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.74.

Current Ratio	1.20
Quick Ratio	0.91
Debt / Equity	0.74
Debt / EBITDA	9.53
Debt / FCF	-8.92
Interest Coverage	0.45

Financial Efficiency

Return on equity (ROE) is 4.77% and return on invested capital (ROIC) is 1.19%.

Return on Equity (ROE)	4.77%
Return on Assets (ROA)	0.92%
Return on Capital (ROIC)	1.19%
Revenue Per Employee	761.55M
Profits Per Employee	30.60M
Employee Count	175
Asset Turnover	0.62
Inventory Turnover	4.00

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -28.58% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-28.58%
50-Day Moving Average	4,603.60
200-Day Moving Average	5,472.75
Relative Strength Index (RSI)	44.59
Average Volume (20 Days)	104,348

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, KUKJEON PHARMACEUTICAL had revenue of KRW 133.27 billion and earned 5.35 billion in profits. Earnings per share was 65.19.

Revenue	133.27B
Gross Profit	24.14B
Operating Income	3.18B
Pretax Income	2.37B
Net Income	5.35B
EBITDA	7.79B
EBIT	3.18B
Earnings Per Share (EPS)	65.19

Full Income Statement

Balance Sheet

The company has 52.41 billion in cash and 74.26 billion in debt, giving a net cash position of -21.85 billion or -445.24 per share.

Cash & Cash Equivalents	52.41B
Total Debt	74.26B
Net Cash	-21.85B
Net Cash Per Share	-445.24
Equity (Book Value)	99.86B
Book Value Per Share	2,021.49
Working Capital	18.85B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 8.40 billion and capital expenditures -16.72 billion, giving a free cash flow of -8.32 billion.

Operating Cash Flow	8.40B
Capital Expenditures	-16.72B
Free Cash Flow	-8.32B
FCF Per Share	-169.58

Full Cash Flow Statement

Margins

Gross margin is 18.12%, with operating and profit margins of 2.39% and 4.02%.

Gross Margin	18.12%
Operating Margin	2.39%
Pretax Margin	1.78%
Profit Margin	4.02%
EBITDA Margin	5.85%
EBIT Margin	2.39%
FCF Margin	-6.24%

Dividends & Yields

This stock pays an annual dividend of 10.00, which amounts to a dividend yield of 0.23%.

Dividend Per Share	10.00
Dividend Yield	0.23%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	9.16%
Buyback Yield	-5.99%
Shareholder Yield	-5.75%
Earnings Yield	1.51%
FCF Yield	-3.92%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

KUKJEON PHARMACEUTICAL has an Altman Z-Score of 2.44. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	2.44
Piotroski F-Score	n/a